RUSNANO

RUSALOX is a high-tech company based in Moscow, Russia, specializing in the development and manufacturing of circuit plates and substrates with high thermal conductivity. Founded in 2010, RUSALOX utilizes a unique aluminum oxide technology that enhances cooling efficiency for heat-dissipating electronic components. Their product offerings include multilayer and one-layer plates, as well as heat-conducting substrates designed for various applications, such as Chip-On-Board technologies, microwave electronics, and advanced packaging systems. The company's innovative substrates feature a patented design that combines an insulating layer on a metal core with a circuit layer, resulting in superior heat dissipation compared to traditional organic PCBs. This allows for high-density integration of electronic components on a single substrate, addressing the increasing challenges of heat generation in multifunctional electronics. RUSALOX's products are noted for their competitive pricing and performance, comparable to standard ceramics.

RMT Ltd. is a manufacturer based in Moscow, Russia, specializing in the development and production of thermoelectric cooling (TEC) modules and devices for optoelectronic applications. The company offers a broad range of over 2,000 miniature thermoelectric coolers designed for various sectors, including telecommunications, industrial, medical, and aerospace. RMT's product lineup includes TEC modules, micro cooling sub-mounts, TEC controllers, diagnostic devices, and optical gas analyzers, as well as software for optimizing cooling solutions. RMT is noted for its commitment to quality, holding ISO 9001 certification, and is the only Russian company certified by the Russian State Space Agency to provide thermoelectric coolers for aerospace applications. With additional sales operations in Berlin and China, RMT aims to deliver high-quality standard and customized cooling solutions while ensuring superior customer service.

NTpharma provides GMP production of nanovaccines and biopharmaceuticals containing carbohydrate binders. The project provides for building a facility for production of vaccines and pharmaceuticals in the municipal area of Pereslavl’-Zalessky, 150 kilometers (85 miles) northeast of Moscow. The project aims at production of new generation vaccines, including a polyvalent human flu vaccine, and pharmaceuticals for detoxification in oncological therapy and for treatment of amyotrophic lateral sclerosis (ALS/Lou Gehrig’s disease). NTpharma’s technology allows to reduce by half the time required for culturing and production of the vaccine. This advantage is vital when dealing with vaccines for pandemic flu strains spreading rapidly all over the world.